Dr. Thomas W. Arnold, M.D.
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Medical school
- University of Tennessee, Hsc, College of Medicine (1983)
- Years since graduation
- 43
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 398
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1983Medical school: University of Tennessee, Hsc, College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
TN license MD015615
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Baptist Memorial Hospital Memphis, TN
- Baptist Memorial Hospital Desoto Southaven, MS
Medical groups
- Neurology Clinic, PC (10 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 398
- Services billed
- 5,092
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, gadoterate meglumine, 0.1 ml | 3,500 | 22 |
| Established patient office or other outpatient visit, 40-54 minutes | 265 | 194 |
| Established patient office or other outpatient visit, 30-39 minutes | 242 | 190 |
| Needle measurement of electrical activity in arm or leg muscles, complete study | 134 | 100 |
| Established patient office or other outpatient visit, 20-29 minutes | 70 | 63 |
| Needle measurement of electrical activity in arm or leg muscles, limited study | 60 | 46 |
| Nerve conduction, 7-8 studies | 53 | 53 |
| Nerve conduction, 9-10 studies | 26 | 26 |
| Mri scan of brain without contrast | 21 | 21 |
| Mri scan of brain before and after contrast | 21 | 21 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 30 companies reported 167 payments worth $3,171 in total to this clinician.
| Teva Pharmaceuticals USA, Inc. | $356 |
|---|---|
| AbbVie Inc. | $342 |
| Novartis Pharmaceuticals Corporation | $303 |
| Tg Therapeutics, Inc. | $297 |
| UCB, Inc. | $261 |
| Argenx US, Inc. | $172 |
| Pfizer Inc. | $152 |
| Genentech USA, Inc. | $143 |
| Food and Beverage | $2,976 |
|---|---|
| Education | $195 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. Dec 17, 2025 | Education in-kind | $111 |
| Teva Pharmaceuticals USA, Inc. Dec 8, 2025 | Education in-kind | $83.99 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 4 companies. The companies reported $415,600 in research payments for these studies, mostly to the institutions running them.
- A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
Eli Lilly and Company · Active, not recruiting · NCT05738486 - Roll Over Protocol for 3 OCR Pivotal Studies Opera I OPERA II and Oratorio to extend the OLE
F. Hoffmann-la Roche AG - A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for the Treatment of Cognitive Impairment Associated with Mild-to-Moderate Alzheimer…
E.r. Squibb & Sons, L.l.c. - A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)
Eli Lilly and Company · Active, not recruiting · NCT05026866 - A Phase 2, Randomized, Double-blind, Three-Arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of orally administered BMS-986368, a FAAH/MAGL Inhibitor, for the treatment of Agit…
Celgene Corporation - A Phase 2, Randomized, Double-blind, Three-Arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of orally administered BMS-986368, a FAAH/MAGL Inhibitor, for the treatment of Agit…
E.r. Squibb & Sons, L.l.c. - Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT06808984 - A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)
E.r. Squibb & Sons, L.l.c. · Recruiting · NCT06929273
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.